我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 Valneva
相关临床试验
56
16 进行中
药物批准
6
批准总数
监管机构
3
监管机构数
成立时间
N/A
进行中（未招募）
14
25.0%
已完成
36
64.3%
Enrolling By Invitation
2
3.6%
撤回
4
7.1%
EMA
European Medicines Agency
CANADA
Health Canada
CIMA_AEMPS
Spanish Agency for Medicines and Medical Devices
- A phase 3b trial of VLA1553 showed that chikungunya virus-neutralizing antibodies persisted for up to two years post-vaccination. - Seroprotection rates remained high, at or above 97% at one year and 96.8% at two years, across all age groups studied. - The study found no long-term safety concerns related to VLA1553, with serious adverse events deemed unrelated to the vaccine. - These findings support VLA1553's potential for active immunization in individuals living in or traveling to chikungunya-endemic areas.
